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Background/aim: Bacteremia remains an important cause of morbidity and mortality during febrile neutropenia (FN) episodes. We
aimed to define the risk factors for bacteremia in febrile neutropenic children with hemato-oncological malignancies.
Materials and methods: The records of 150 patients aged ≤18 years who developed FN in hematology and oncology clinics were
retrospectively evaluated. Patients with bacteremia were compared to patients with negative blood cultures.
Results: The mean age of the patients was 7.5 ± 4.8 years. Leukemia was more prevalent than solid tumors (61.3% vs. 38.7%). Bacteremia
was present in 23.3% of the patients. Coagulase-negative staphylococci were the most frequently isolated microorganism. Leukopenia,
severe neutropenia, positive peripheral blood and central line cultures during the previous 3 months, presence of a central line, previous
FN episode(s), hypotension, tachycardia, and tachypnea were found to be risk factors for bacteremia. Positive central line cultures
during the previous 3 months and presence of previous FN episode(s) were shown to increase bacteremia risk by 2.4-fold and 2.5-fold,
respectively.
Conclusion: Presence of a bacterial growth in central line cultures during the previous 3 months and presence of any previous FN
episode(s) were shown to increase bacteremia risk by 2.4-fold and 2.5-fold, respectively. These factors can predict bacteremia in children
with FN.
Key words: Bacteremia, children, febrile neutropenia, risk factor

1. Introduction
Febrile neutropenia (FN) is a leading cause of infectious
mortality for patients receiving cytotoxic chemotherapies.
Approximately one-third of children with cancer treatment
or hematopoietic stem cell transplantation experience FN
during the neutropenic period [1]. During these episodes,
bacteremia remains one of the most important causes of
morbidity and mortality due to serious complications.
Neutropenia significantly changes the inflammatory
response of the host, and it is therefore difficult to identify
infections. Documented infectious etiology is encountered
in only 20%–30% of febrile neutropenic patients [2].
Blood culture remains the mainstay for the diagnosis of
bacteremia. Bacterial isolation rates using the conventional
technique vary between 25%–80% depending on the
clinical situation of children with FN [3]. Thus, defining

the risk factors is crucial for rapid and prompt diagnosis
and eventual appropriate treatment in order to obviate
high rates of morbidity and mortality.
Although some risk stratifications have been suggested
to identify low-risk episodes of FN in adults, fever is
sometimes the only sign of severe and life-threatening
infections in neutropenic children with cancer [4]. There
is no validated risk scoring system for children with FN
to determine the high-risk groups for development of
bacteremia, but some clinical parameters such as diagnosis
of leukemia [5], induction type chemotherapy [6],
neutropenia for longer than 7 days [5,7], body temperature
of over 39 °C at the time of FN diagnosis [8], presence
of chills or hypotension and the need for resuscitation
[9], presence of central venous catheters (CVCs) [10],
and laboratory parameters such as increased C-reactive
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protein, procalcitonin and interleukin levels [5,11,12],
and absolute neutrophil counts of ≤200/mm3 have been
proposed previously in children and adults.
In this study, we aimed to investigate the presence of
risk factors for bacteremia in febrile neutropenic children
with hemato-oncological malignancies.
2. Materials and methods
2.1. Study design and patient population
The records of 150 pediatric patients aged 18 years and
younger with hemato-oncological malignancies who
developed FN in the hematology and oncology clinics
of the Gazi University Medical Faculty and the Ankara
Hematology Oncology Children’s Training and Research
Hospital from 1 January 2014 to 31 December 2015
were retrospectively evaluated. The data of patients with
hematopoietic stem cell transplantation, patients who did
not fulfill the criteria for FN, and patients with fungemia
were excluded. Only the first FN episode of each patient
during this period was included and subsequent episodes
were not included.
2.2. Data collection
The medical records of the enrolled patients were collected,
including clinical characteristics and laboratory findings
on the first day of FN episode: age, sex, primary diagnosis,
presence of previous FN episode(s), duration since the last
chemotherapy administration, type of last chemotherapy,
duration and severity of neutropenia, duration and
maximum value of fever, duration of hospitalization,
antibiotic usage (type and duration), presence of
hypotension, tachycardia, tachypnea, focal infection,
indwelling catheter (central line [central venous catheter
or implantable port] and urinary catheter), and laboratory
parameters (white blood cell count [WBC], absolute
neutrophil count [ANC], hemoglobin, platelet count,
C-reactive protein [CRP], erythrocyte sedimentation rate
[ESH], abnormality in liver and renal functions, electrolyte
imbalance, urine analysis and growth in peripheral blood
and central venous catheter [CVC]/implantable port [IP],
urine cultures, and cultures from other sites, such as skin
lesions, cerebrospinal fluid [CSF], throat, or stools [if
present]). Also, positivity in peripheral blood and/or CVC/
IP cultures during the previous 3 months was recorded.
The study was approved by the local ethics committee
(date: 05/17/2016; number: 2016-10-65).
2.3. Definitions
Febrile neutropenia is defined as a fever, which is a single
measurement of ≥38.3 °C or a temperature of ≥38 °C
lasting for over 1 h, plus an ANC of <500/mm3 or expected
to decrease <500/mm3 within 48 h [13]. The maximum
value of fever at the time of diagnosis was the highest
documented value of the body temperature measured in

the emergency department/clinic until FN diagnosis was
established. Hypotension was defined as systolic blood
pressure below the fifth percentile for age and sex, or the
need for vasopressor support. Tachycardia was defined
as mean heart rate >2 standard deviations (SDs) above
normal for age, not resulting from external stimulus,
chronic drugs, or painful stimuli. Tachypnea was defined
as mean respiratory rate >2 SDs above normal for age.
Duration since last chemotherapy was the sum of days
passed since the first day of the last chemotherapy period.
Two sets of blood culture from two separate veins were
drawn from each patient at the time of FN diagnosis. If
present, blood samples were also obtained from each
lumen of any central line. Collected blood samples were
placed into BACTEC culture vials and cultures were
determined to be positive by an automated continuous
monitoring system (BACTEC 9240; Becton Dickson,
Sparks, MD, USA). Bacteremia was defined as the isolation
of a significant pathogen from one or more blood cultures
that was not a contaminant when the patient had clinical
symptoms and signs of infection. After discriminating
between true bacteremia and contamination, all cases
fulfilling the CDC-NHSN definition of clinically significant
bloodstream infection were included [14]. Coagulasenegative staphylococci (CNS) are the most frequent
contaminants of blood cultures. To distinguish true
infection from contamination, the presence of systemic
manifestations of infection, such as tachycardia, tachypnea,
and hypotension in addition to fever was noted, or at least
two separate positive blood culture results repeated 1–2
days apart from each other were considered as positive to
render the diagnosis of true infection relatively secure.
2.4. Statistical analysis
Statistical analyses were performed using SPSS 18 (SPSS
Inc., Chicago, IL, USA). The Shapiro–Wilk test was used
to investigate whether the continuous variables were
normally distributed. Descriptive analyses were presented
using means and standard deviations and medians and
minimum–maximum for normally and nonnormally
distributed variables, respectively. If normally distributed,
an independent t samples test was used, and if not normally
distributed, the Mann–Whitney U test was used to
compare two independent groups. Chi-square or Fischer
exact tests were used for comparisons between categorical
variables. The variables that turned out to be significant
for bacteremia after univariate analysis (white blood cell
count, presence of central line, severity of neutropenia at
admission, presence of previous FN episode(s), positivity
in peripheral blood, and CVC/IP cultures during previous
3 months) were included in regression analyses (enter
model) to explore independent risk factors for bacteremia.
P < 0.05 was considered to show a statistically significant
result.
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3. Results
One hundred and fifty patients were enrolled in the study.
The mean age of the children was 7.5 ± 4.8 years (range: 3.6
months to 18 years) and the male/female ratio was 1.5 (92
[61.3%] / 58 [38.7%]). Leukemia was more prevalent than
solid tumors (61.3% vs. 38.7%). Other clinical characteristics
of the study population are shown in Table 1.
Laboratory characteristics of the study population
are shown in Table 2. Thirty-five (23.3%) patients were
shown to have blood culture positivity. Eleven (31.4%)
CNS (penicillin-sensitive, 3 [8.5%]; oxacillin-sensitive,
3 [8.5%]; and oxacillin-resistant, 5 [14.2%]), 6 (17.1%)
Escherichia coli, 5 (14.2%) Klebsiella pneumoniae, 4
(11.4%) Staphylococcus aureus (penicillin-sensitive,
3 [8.5%]; oxacillin-resistant, 1 [2.8%]), 4 (11.4%)
Stenotrophomonas maltophilia, 2 (5.7%) Enterococcus
faecalis (vancomycin-sensitive), 1 (2.8%) alpha-hemolytic
streptococcus, 1 (2.8%) Pseudomonas aeruginosa, and
1 (2.8%) Pseudomonas oryzihabitans growths were seen
in blood cultures. No mixed infections were observed.
Eleven (7.3%) patients who also had peripheral blood
culture positivity had growth in the CVC/IP culture. The
pathogens were as follows: CNS, 5 (45.4%); Escherichia
coli, 3 (27.2%); Klebsiella pneumoniae, 2 (18.1%); and
Pseudomonas aeruginosa, 1 (9.0%). No mixed infections
were observed. Ten (6.7%) patients had urinary culture
positivity; no patients had CSF or stool culture positivity.
Patients with peripheral blood culture positivity were
compared with patients with negative blood cultures to
demonstrate the risk factors for bacteremia during an
FN episode (Table 3). White blood cell count, severity of
neutropenia at admission, positivity in peripheral blood
and central line cultures during the previous 3 months,
presence of a central line, presence of previous FN
episode(s), and presence of hypotension, tachycardia, and
tachypnea were risk factors for bacteremia (P = 0.02, P =
0.01, P = 0.01, P < 0.0001, P = 0.03, P = 0.001, P < 0.0001,
P < 0.0001, and P = 0.003, respectively).
In regression analyses, positivity in central line cultures
during the previous 3 months (OR: 2.44; 95% CI: 1.16–
5.12, P = 0.01) and presence of previous FN episode(s)
(OR: 2.55; 95% CI: 1.27–5.15, P = 0.009) were shown to
be independently associated with bacteremia in febrile
neutropenic children, as shown in Table 4.
4. Discussion
In this study, the risk factors related to bacteremia in
children with FN were investigated in two centers in a
developing country. In general, although most episodes of
FN are assumed to result from an infection, blood cultures
were positive in less than 30% of febrile neutropenic
episodes [15]. Similar to the literature, the present study
had a rate of bacteremia of 23.3%.
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Children with FN are a heterogeneous group with a
varying risk of severe infection or medical complications.
Management of infectious complications in these patients
requires the definition and extinguishment of the risk
factors. Knowledge regarding the previous history of
FN and the risk of subsequent febrile episodes might be
useful at the beginning of any chemotherapy-induced
granulocytopenic period in order to decide on prophylactic
or interventional strategies [16]. Although there are
conflicting reports about this association in the literature,
in this study, 69.3% of the patients had experienced at least
one FN episode previously, and the presence of a history of
FN episode(s) was shown to increase the risk of bacteremia
in febrile neutropenic children by approximately 2.5 times
for latter episodes [16–18]. Additionally, it was previously
concluded that more than three previous FN episodes
were related to adverse outcomes such as mortality,
invasive infections, and hemodynamic instability in febrile
neutropenic patients [19].
The results of this study revealed that positivity
in central line cultures during the previous 3 months
increased the risk of bacteremia by approximately 2.4
times. Having a history of bacteremia during the last 3
months was associated with bacteremia. In the literature,
any previously documented infection in the past 6 months
was shown to be a risk factor in pediatric FN for serious
medical complications, including a microbiologically
defined infection [20]. Catheter-associated blood stream
infections are frequently seen during cancer treatment.
Recurrent bacteremia in children with FN has been
documented mostly when infected catheters could not
be removed because of catheter salvage attempts [21].
Pathogens form a biofilm layer and hide from the killing
effect of antibiotics. Additionally, any previous bacteremia
due to other pathogens may lead to subsequent bacteremia
in the host with more resistant pathogens [22]. However,
such an association was not obtained in this study.
Rondinelli et al. [10] reported that central lines were a
risk factor for severe infectious complications, including
bacteremia in FN patients. In this study, most of the
patients had a central line, of which the majority were
CVCs. It was found that the presence of a central line was
associated with bacteremia in children with FN. Similarly,
Al Omar et al. [23] stated that positive blood cultures
were significantly more frequent in episodes with a CVC
compared with episodes with no CVC. Additionally, CVCs
are also a reason for bloodstream infections by multidrugresistant bacteria [24].
This study revealed that patients with hypotension,
tachycardia, and tachypnea were more prone to have
bacteremia. In addition to the instability of these vital signs,
the presence of abnormal body temperature or leukocyte
count, together with suspected/present source of infection,
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Table 1. Clinical characteristics of the study population (n = 150).
n (%)
Primary diagnosis
a
Leukemia
b
Solid tumor

92 (61.3%)
58 (38.7%)

Presence of previous FN episode(s)

104 (69.3%)

Duration since the last chemotherapy administered (days) [median (min–max)]

8 (0–50)

Type of the last chemotherapy
Induction
Consolidation
Maintenance

93 (62%)
41 (27.3%)
16 (10.7%)

Duration of neutropenia
<7 days
≥7 days

93 (62%)
57 (38%)

Severity of neutropenia at admission
<100/mm3
100–500/mm3

102 (68%)
48 (32%)

Duration of fever at the time of blood drawn
First 12 h
12–24 h
>48 h

138 (92%)
11 (7.3%)
1 (0.7%)

Duration of hospitalization at admission
Hospitalized for ≥48 h
Coming from home

88 (58.7%)
62 (41.3%)

Prophylactic or treatment antibiotic usage at the time of diagnosis

85 (56.7%)

Tachycardia

6 (4.0%)

Hypotension

6 (4.0%)

Tachypnea

4 (2.6%)

Focal infection/inflammation
URTI
Oral mucositis
Gastroenteritis
Pneumonia
Anal abscess
Cellulitis
UTI
Dental carries
Infection at catheter entrance site
Typhlitis
Zona infection

98 (65.3%)
50 (33.3%)
41 (27.3%)
21 (14.0%)
7 (4.7%)
6 (4.0%)
5 (3.3%)
4 (2.7%)
2 (1.3%)
2 (1.3%)
2 (1.3%)
1 (0.6%)

Presence of central line
Central venous catheter
Port device

107 (71.3%)
81 (54.0%)
26 (17.3%)

Presence of urinary catheter

9 (6.0%)

Max value of fever at the time of diagnosis (°C) (mean ± SD)

38.4 ± 0.3

SD, standard deviation; FN, febrile neutropenia; min, minimum; max, maximum.
a
Acute lymphoblastic leukemia (ALL), 64 (42.7%); acute myeloblastic leukemia (AML), 20 (13.3%);
juvenile myelomonocytic leukemia, 2 (1.3%); relapse ALL, 4 (2.7%); relapse AML, 1 (0.7%).
b
Non-Hodgkin lymphoma/Burkitt lymphoma, 12 (8%); neuroblastoma, 12 (8%); Ewing sarcoma, 10
(6.7%); rhabdomyosarcoma, 4 (2.7%); retinoblastoma, 4 (2.7%); medulloblastoma, 3 (2%); Hodgkin
lymphoma, 2 (1.3%); germ cell tumor, 2 (1.3%); yolk sac tumor, 2 (1.3%); rhabdoid tumor, 2 (1.3%);
glioblastoma multiforme, 1 (0.7%); oligodendroglioma, 1 (0.7%); synovial sarcoma, 1 (0.7%); primitive
neuroectodermal tumor (PNET), 1 (0.7%); ependymoma, 1 (0.7%); astrocytoma, 1 (0.7%); SD, standard
deviation; URTI, upper respiratory infection; UTI, urinary tract infection.
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Table 2. Laboratory characteristics of the study population (n = 150).
Parameter

Value

WBC (/µL) [median (min–max)]

600 (0–26,500)

ANC (/µL) [median (min–max)]

40 (0–500)

Hemoglobin value (g/dL) (mean ± SD)

8.8 ± 1.5

Platelet count (/µL) (median [min–max])

38,550 (3200–559,000)

CRP level (0–5 mg/dL) [median (min–max)]

28.5 (1–438)

ESH (0–20 mm/h) (mean ± SD)

52.5 ± 32.6

Growth in peripheral blood culture, n (%)

35 (23.3%)

Growth in central line culture, n (%)

11 (7.3%)

Presence of urinary tract infection, n (%)

10 (6.7%)

Positivity in peripheral blood culture during previous 3 months, n (%)

37 (24.7%)

Positivity in central line culture during previous 3 months, n (%)*

31 (20.7%)

Abnormality in liver functions, n (%)

39 (26%)

Abnormality in renal functions, n (%)

4 (2.7%)

Electrolyte imbalance, n (%)

15 (10%)

WBC, white blood cell count; ANC, absolute neutrophil count; CRP, C-reactive protein; ESH, erythrocyte
sedimentation rate; *, central venous catheter or implantable port.

Table 3. Univariate analysis of risk factors of bacteremia in children with FN.
Parameter, n (%)

Bacteremia (+)

Bacteremia (–)

P-value

WBC (/µL) [median (min–max)]

420 (0–3150)

600 (80–26,500)

0.02

Severity of neutropenia at admission
<100/mm3
100–500/mm3

30 (85.7%)
5 (14.2%)

72 (62.6%)
43 (37.3%)

0.01

Positivity in peripheral blood culture during previous 3 months, n (%)

14 (40.0%)

23 (20.0%)

0.01

Positivity in central line culture during previous 3 months, n (%)*

15 (42.8%)

16 (13.9%)

<0.0001

Presence of central line*

30 (85.7%)

77 (67.0%)

0.03

Presence of previous FN episode(s)

32 (91.4%)

72 (62.6%)

0.001

Hypotension

6 (17.1%)

0 (0%)

<0.0001

Tachycardia

6 (17.1%)

0 (0%)

<0.0001

Tachypnea

4 (11.4%)

0 (0%)

0.003

FN, febrile neutropenia; WBC, white blood cell count; *, central venous catheter or implantable port.

Table 4. Logistic regression analysis of risk factors for bacteremia in children with FN.
Independent risk factor

B

S.E.

Wald

Odds
ratio

Confidence
interval (95%)

P-value

Positivity in central line culture during previous 3 months, n (%)*

0.89

0.377

5.64

2.44

1.16–5.12

0.01

Presence of previous FN episode(s)

0.93

0.35

6.91

2.55

1.27–5.15

0.009
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is defined as sepsis. It was shown that over 50% of patients
with FN develop sepsis syndrome, 20%–30% develop severe
sepsis, and 5%–10% develop septic shock [25]. The NICE
guidelines noted that the presence of hypotension and
tachypnea were high risk factors for septic complications
[26]. Although Asturias et al. [27] found no relationship
between bacteremia and the simultaneous presence of
hypotension, other studies reported that the presence of
hypotension together with prolonged capillary refill time,
fever above 39 °C, and pneumonia was related to invasive
bacterial infections and fatal outcomes in bacteremic
episodes in children with FN [11,28]. Additionally, “sick”
or unwell general clinical appearance on admission was
noted as a clue for significant/proven bacterial infection in
children with FN [29].
Infectious complications seen in the neutropenic host
are a direct result of faulty defense; a clear relationship
is present with neutropenia, which develops because of
the extended use of high-dose chemotherapeutics. The
degree, rapidity of onset, and duration of neutropenia
directly affect the rate and severity of infections because
of diminished phagocytic activity of neutrophils against
bacteria [30]. Previous reports stated that ANC of <100/
mm3 was shown to predict the risk of invasive bacterial
infections in pediatric cancer patients with fever and
neutropenia [26,29]. Similarly, in this study, ANC of <100/
mm3 and lower WBC were associated with bacteremia.
Several other factors have been reported to have an
association with bacteremia in children with FN. Children
younger than 5 years old and with primary disease
diagnoses such as ALL/Burkitt lymphoma, induction
phase of ALL, and primary progressive or relapsed
disease with bone marrow involvement were more
prone to septic complications [10,26,31]. However, no
relationship was observed with blood culture positivity in
this study. Also, although we did not find an association,
prolonged neutropenia, body temperature over 39 °C,
recent chemotherapy (≤7 days), and presence of any focal

infection were noted to be predictors of bacteremia, as well
as acute phase reactants [5,11,26,29]. Previous treatment
and prophylactic use of antibiotics are important
risk factors for developing serious bacteremia during
neutropenia [32]. Although more than half of the studied
children were using antibiotics at the time of FN diagnosis,
it was not associated with bacteremia.
While gram-negative pathogens were formerly
predominant, increased use of indwelling catheters,
quinolone prophylaxis, and broad-spectrum empirical
antibacterial therapy led to an increase in the incidence of
infections with gram-positive pathogens in cancer patients
during the last decades [2]. CNS account for the majority
of blood stream infections in children undergoing therapy
for malignancy [33,34]. Similarly, in this study, the most
common bacterial etiologic agents isolated from blood
cultures were CNS. Above all, for a general appropriate
approach to infectious complications in neutropenic
cancer patients, it is required to obtain knowledge of the
local epidemiology of infections, the causative organisms,
and their resistance phenotype.
The retrospective design and indigenous disadvantages
of blood culture are limitations of this study. Molecular
techniques, such as polymerase chain reaction, could
have amplified the success of bacterial identification rates,
as even the effects of previous antibiotic exposure are
omitted. Conventional methods have the ability to yield
a microorganism in rates of 40% in children with clinical
sepsis and 75% in high-risk febrile neutropenic children
[35–37].
In conclusion, the association of possible risk factors
related to bacteremia in children with FN was investigated
in this study. The presence of any bacterial growth in CVC/
IP cultures during the previous 3 months and the presence
of previous FN episode(s) before the study period were
found to be risk factors for bacteremia. We suggest that
each patient must be evaluated individually for their own
risk factors before the management of FN episodes.
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